AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9694050
Drug: Purified nucleohistone-binding
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified nucleohistone-binding antibodies from anti-DNA-depleted plasma IgG
Trial: 9694050
Drug: Purified antibodies
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified antibodies from nephritis patient
Trial: 9694050
Drug: Adsorption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adsorption of purified antibodies with histone
Trial: 28731778
Drug: Pharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic treatment algorithm
Trial: 28731778
Drug: At least
RxNorm normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At least one psychiatric medication
Trial: 25278336
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (detuned ultrasound and shortwave therapy)
Trial: 19390751
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg riboflavin daily for 28 days
Trial: 15120716
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of stearidonic acid (1g/day) and gamma-linolenic acid (0.9g/day)
Trial: 15120716
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EPA with gamma-linolenic acid (GLA)
Trial: 7235853
Drug: Weekly supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly supportive group meetings
Trial: 20100408
Drug: 0.3% nifedipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% nifedipine and 1.5% lidocaine ointment
Trial: 20100408
Drug: 1.5% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% lidocaine ointment alone
Trial: 15817854
Drug: bIg (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bIg (5 g)
Trial: 10609394
Drug: Proximal adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proximal adenosine infusion (108 to 3456 micrograms/min for 2 min)
Trial: 10609394
Drug: Distal adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Distal adenosine infusion (108 to 3456 micrograms/min for 2 min)
Trial: 8836079
Drug: Bone-patellar tendon-bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-patellar tendon-bone autograft with Kennedy ligament augmentation device
Trial: 8836079
Drug: Bone-patellar tendon-bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-patellar tendon-bone autograft without Kennedy ligament augmentation device
Trial: 1426214
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (A), 50-100 mg daily
Trial: 30672231
Drug: Conventional western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medication (Diazepam, 2.5 mg/day)
Trial: 30672231
Drug: Placebo (starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch capsule, once a day)
Trial: 30672231
Drug: Conventional western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional western medication (Diazepam)
Trial: 8704426
Drug: Placebo (starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch capsule)
Trial: 24842649
Drug: Bupropion (150/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (150/300 mg/day) + Duloxetine (60 to 120 mg/day)
Trial: 24842649
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Duloxetine (60 to 120 mg/day)
Trial: 20461807
Drug: Perampanel 2
RxNorm normalized name: perampanel 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel 2 mg
Trial: 29157034
Drug: Pregabalin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150 mg)
Trial: 3722507
Drug: 1% topical
RxNorm normalized name: SSD 1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% topical minoxidil
Trial: 16240515
Drug: Clindesse vaginal
RxNorm normalized name: Clindesse Vaginal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindesse vaginal cream (single dose)
Trial: 16240515
Drug: Cleocin vaginal
RxNorm normalized name: Cleocin Vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cleocin vaginal cream (7 doses)
Trial: 10948088
Drug: N(G)‐monomethyl‐L‐arginine (L‐NMMA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)‐monomethyl‐L‐arginine (L‐NMMA)
Trial: 10981082
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (enalapril, captopril)
Trial: 10981082
Drug: Beta-blockers (atenolol)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (atenolol)
Trial: 10981082
Drug: Calcium-channel blockers
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-channel blockers (long-acting nifedipine)
Trial: 10981082
Drug: Diuretics (hydrochlorothiazide)
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (hydrochlorothiazide)
Trial: 2351368
Drug: Cyproheptadine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine (6 mg)
Trial: 2351368
Drug: DL Carnitine
RxNorm normalized name: DL-CARNITINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL Carnitine (1600 mg)
Trial: 24090258
Drug: Topical decolonization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical decolonization with intranasal mupirocin twice daily plus 4% chlorhexidine gluconate body wash daily for 5 days before surgery
Trial: 24090258
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics (cephalexin) with statim pre- and postoperative doses
Trial: 22117991
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg i.v. over 10 min followed by 0.2 - 0.7 μg/kg per h continuous i.v. infusion)
Trial: 22117991
Drug: Remifentanil (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.8 - 1.2 μg/kg i.v. over 1 min followed by 0.05 - 0.1 μg/kg i.v. per min)
Trial: 11327055
Drug: ePTFE combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ePTFE combined with weekly repeated local application of minocycline ointment for 8 weeks after membrane placement
Trial: 9623035
Drug: Regular surveillance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular surveillance using a simple questionnaire administered by non-professional personnel (cases)
Trial: 7929726
Drug: Clonidine test
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine test to explore the ability of the pituitary to release growth hormone
Trial: 7929726
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of anti‐granulosa cell auto‐antibodies in blood using an enzyme‐linked immunosorbent assay (ELISA)
Trial: 3791153
Drug: Hydrazine sulfate
RxNorm normalized name: Hydrazine Sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrazine sulfate (60 mg, 3 times/d)
Trial: 22993101
Drug: lopinavir/ritonavir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir monotherapy (mLPV/r)
Trial: 11718517
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg melatonin
Trial: 8524494
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (500 mg intravenously after haemodialysis, 1-3 times a week)
Trial: 1914619
Drug: Terfenadine, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine, 120 mg
Trial: 25327884
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate (CIT) 900 mg kg(‐1)
Trial: 17314114
Drug: 1.0 kcal/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 kcal/ml nocturnal enteral feed (NEF)
Trial: 17314114
Drug: 1.5 kcal/ml
RxNorm normalized name: lactose-reduced food 0.05 gram-1.5 kcal/mL ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 kcal/ml nocturnal enteral feed (NEF)
Trial: 9489937
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg oral caffeine
Trial: 9489937
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg oral caffeine
Trial: 9489937
Drug: 0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/kg oral caffeine (control group)
Trial: 7827353
Drug: Diabetic patients
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic patients before treatment
Trial: 2901252
Drug: Neuroleptic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic treatment (medication continued)
Trial: 2901252
Drug: Drug-withdrawn patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-withdrawn patients (some clinically relapsed)
Trial: 28794291
Drug: Allopurinol, 100
RxNorm normalized name: Allopurinol, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol, 100 mg daily for 12 months
Trial: 27004309
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTxA) injection (20 IU, 0.2 ml)
Trial: 27004309
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution injection (0.2 ml)
Trial: 23094638
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg + Amlodipine 10 mg
Trial: 21193281
Drug: Experiential‐existential therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiential‐existential therapy groups
Trial: 17182297
Drug: Alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 10 mg/day (ALN)
Trial: 17314736
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day (RLX)
Trial: 11505331
Drug: STW‐5 (herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STW‐5 (herbal preparation containing bitter candy tuft and other extracts)
Trial: 11505331
Drug: STW‐5‐S (modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STW‐5‐S (modified preparation without bitter candy tuft)
Trial: 2676440
Drug: Ketanserin (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (20-40 mg twice a day)
Trial: 30799474
Drug: K-etchant GEL
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-etchant GEL (KE)
Trial: 20491814
Drug: Group E
RxNorm normalized name: Prostaglandin group E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group E (control, no bone augmentation)
Trial: 17489080
Drug: Circumferential sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circumferential sequential gradient compression (CSG)
Trial: 17489080
Drug: Posterior sequential
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior sequential rapid gradient inflation device (PSR)
Trial: 12394199
Drug: Salt tablets
RxNorm normalized name: bile salts Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt tablets (approximately 700 mg/h of sodium)
Trial: 31524133
Drug: Behavioural Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural Activation (BA) therapy, up to 15 sessions over 4 months.
Trial: 31524133
Drug: Behavioural Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural Activation (BA) therapy.
Trial: 24215565
Drug: Artemisinin-naphthoquine (ANQ)
RxNorm normalized name: naphthoquine
DrugBank: Naphthoquine (DB16249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin-naphthoquine (ANQ) - total target dose of 24.5 mg/kg (naphthoquine 7 mg/kg and artemisinin 17.5 mg/kg), once a day for three days
Trial: 24215565
Drug: Chloroquine-primaquine (CQ-PQ)
RxNorm normalized name: chloroquine / primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine-primaquine (CQ-PQ) - total CQ dose of 24 mg base/kg, once a day for three days plus PQ dose of 0.45 mg base/kg/day, once a day for eight days
Trial: 1449620
Drug: Simple chemotherapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple chemotherapy regimens
Trial: 1449620
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy regimens
Trial: 31960409
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion thresholds (105 g/l, maintaining 110-125 g/l)
Trial: 31960409
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion thresholds (80 g/l, to maintain haemoglobin 85-100 g/l)
Trial: 27455842
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg peri-articular TXA
Trial: 27455842
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg IV TXA
Trial: 24325778
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Simvastatin and Bezafibrate
Trial: 15628812
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (Lantus)
Trial: 18715206
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (Apidra)
Trial: 15741724
Drug: 20% (w/v)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% (w/v) sucrose plus 70 microg Fe/ml
Trial: 15741724
Drug: 20% (w/v)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% (w/v) sucrose plus 18 microg Fe/ml
Trial: 10800070
Drug: CD34+ cell
RxNorm normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD34+ cell dose greater than 5 x 106/kg
Trial: 10800070
Drug: CD34+ cell
RxNorm normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD34+ cell dose higher than 5 x 106/kg
Trial: 10800070
Drug: CD34+ cell
RxNorm normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD34+ cell dose lower than 5 x 106/kg
Trial: 8471413
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg)
Trial: 19855988
Drug: Fluoroscopy-guided thermal
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroscopy-guided thermal ablation therapy
Trial: 8712826
Drug: MMC (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMC (4 mg, twice a week, total 1 mg/kg) + OK-432 (or PSK)
Trial: 8712826
Drug: MMC +
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMC + OK-432 + HCFU (600 mg, per day)
Trial: 4035328
Drug: sn‐polyenylphosphatidylcholin (PPC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sn‐polyenylphosphatidylcholin (PPC) 450 mg b.i.d. (three times daily)
Trial: 24285336
Drug: Supervised walking
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised walking (60 min three times weekly for 3 months)
Trial: 17241101
Drug: Inhaled β2-agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled β2-agonists (formoterol, salbutamol, salmeterol, terbutaline)
Trial: 12153065
Drug: Self-administered history
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered history questionnaire
Trial: 1979796
Drug: Cetirizine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (5 to 20 mg once daily)
Trial: 1979796
Drug: Hydroxyzine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine (25 to 75 mg/day in divided doses)
Trial: 31326304
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral l-arginine plus tadalafil
Trial: 31326304
Drug: Single drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drugs (either l-arginine or tadalafil)
Trial: 23790420
Drug: Night extension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Night extension orthosis plus hand therapy
Trial: 23790420
Drug: Hand therapy
RxNorm normalized name: Octinoxate 3.00 mL in 75 mL / Avobenzone 1.5 mL in 75 mL TOPICAL CREAM [Botanics Daily Hand Therapy Sunscreen SPF 10]
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hand therapy alone
Trial: 18922988
Drug: Hemoglobin target
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin target of 13.5 to 14.5 g/dl
Trial: 18922988
Drug: Hemoglobin target
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin target of 9.5 to 11.5 g/dl
Trial: 11137633
Drug: Newer generation
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer generation dentine‐bonding agents
Trial: 7869013
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 to 8 mg) monotherapy
Trial: 7869013
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 to 8 mg) in combination with hydrochlorothiazide (50 mg/day)
Trial: 2832030
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH, Enoxaparine) 60 mg daily
Trial: 2832030
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH, Enoxaparine) 40 mg daily
Trial: 2832030
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH, Enoxaparine) 20 mg daily
Trial: 2832030
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UH) 5000 units daily
Trial: 31980285
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg BID)
Trial: 31960705
Drug: Accelerated Resolution
RxNorm normalized name: Revolution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated Resolution Therapy (ART)
Trial: 14703598
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CRP > 10 pg/mL plus IL‐6 > 18 pg/mL at 0-hour
Trial: 10716520
Drug: Beta-blockers (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (n = 33)
Trial: 10716520
Drug: No beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-blockers (n = 32)
Trial: 1641252
Drug: Treatment (expulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (expulsion of Trichuris trichiura)
Trial: 6829944
Drug: Atropine 0.02
RxNorm normalized name: ATROPINE 0.025/DIFENOXIN 1MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.02 mg/kg intramuscularly before induction
Trial: 31860965
Drug: N2O titration
RxNorm normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N2O titration (30% to ideal sedation concentration)
Trial: 31860965
Drug: N2O titration
RxNorm normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N2O titration
Trial: 22951193
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of methylprednisolonacetate
Trial: 16421163
Drug: Epoetin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin (in vitro treatment of PBMs)
Trial: 12671377
Drug: Thrombin solution
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombin solution (control)
Trial: 1882909
Drug: Sucralfate (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1-g tablet twice a day for 4 months)
Trial: 6133059
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g glucose plus 70 mmol NaHCO3